Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells

Leukemia Research

Volumn 21, Issue 5, 1997, Pages 449-458

  Sedlák, Ján ^a   Hunáková, Luba ^a   Sulikova M ^a   Chorváth, Branko ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Cell cycle alterations; Cell surface antigens; Drug uptake; Flow cytometry; Multidrug resistance; Protein kinase inhibitors

Indexed keywords

CD59 ANTIGEN; DAUNORUBICIN; DNA; GENISTEIN; GLYCOPROTEIN P; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN; MIDOSTAURIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RHODAMINE 123; STAUROSPORINE;

ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; CONTROLLED STUDY; DNA CONTENT; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTIGENS, CD; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL CYCLE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; GENISTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HL-60 CELLS; HLA-DR ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; ISOFLAVONES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; RHODAMINE 123; RHODAMINES; STAUROSPORINE; VINCRISTINE;

EID: 0342618467     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00088-4     Document Type: Article

References (39)

1. Kartner, N., Eversden-Porelle, D., Bradley, G. and Ling, V., Detction of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 1985, 316, 820.
2. Pastan, I. H. and Gottesman, M. M., Molecular biology of multidrug resistance in human cells. Important Advances in Oncology, 1988, 1, 3.
3. Georges, E., Sharom, F. J. and Ling, V., Multidrug resistance and chemosensitization: Therapeutic implications for cancer chemotherapy. Advances in Pharmacology, 1990, 21, 185.
4. Horio, M., Gottesman, M. M. and Pastan, I., ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proceedings of the National Academy of Sciences USA, 1988, 85, 3580.
5. Chambers, T. C., Pohl, J., Raynor, R. L. and Kuo, J. F., Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. Journal of Biology and Chemistry, 1993, 268, 4592.
6. Sampson, K. E., Wolf, C. L. and Abraham, I., Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Letters, 1993, 68, 7.
7. Marsh, W., Sicheri, D. and Center, M. S., Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Research, 1986, 46, 4053.
8. McGrath, T. and Center, M. S., Mechanisms of multidrug resistance in HL60 cells: Evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Research, 1988, 48, 3959.
9. Krishnamachary, N. and Center, M. S., The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Research, 1993, 53, 3658.
10. Bates, S. E., Lee, J. S., Dickstein, B., Spolyar, M. and Fojo, A. T., Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry, 1993, 32, 9156.
11. Efferth, T. and Volm, M., Reversal of doxorubicin resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Letters, 1993, 70, 197.
12. Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Rosel, J., Muller, M., Caravatti, G. and Matter, A., A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. International Journal of Cancer, 1989, 43, 851.
13. Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H. and Hofmann, J., The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. International Journal of Cancer, 1994, 57, 104.
14. Chorvath, B., Sedlak, J. and Novotny, L., The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line. International Journal of Cancer, 1994, 59, 852.
15. Sedlak, J., Hunakova, L., Duraj, J., Chorvath, B. and Novotny, L., Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251 on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anticancer Drugs, 1995, 6, 70.
16. Pleskova, I., Sedlak, J., Duraj, J., Festin, R., Munozova, H., Polakova, K. and Chorvath, B., Monoclonal antibody directed to MHC class I antigen (Bra23/9): characterization and utilization for study of antigen expression in differentiation of U 937 cell line. Neoplasma, 1988, 35, 657.
17. Horejsi, V., Chorvath, B., Polakova, K., Duraj, J. and Sedlak, J., Characterization of a new monoclonal anti-DP (MHC class II) antibody elicited by a non-T, non-B ALL cell line. Tissue Antigens, 1988, 32, 6.
18. Chorvath, B., Hunakova, L., Turzova, M., Sulikova, M., Duraj, J., Speiser, P. and Sedlak, J., Monoclonal antibodies to two adhesive cell surface antigens (CD43 and CD59) with different distribution on hematopoietic and non-hematopoietic tumor cell lines. Neoplasma, 1992, 39, 325.
19. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J., Scheper, R. J. and Zaman, G. J., Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Research, 1994, 54, 4557.
20. Vindelov, L. L., Christensen, I. J. and Nissen, N. I., A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 1983, 3, 323.
21. Nuti, M., Zupi, G., D'Agnano, I., Turchi, V., Candiloro, A. and Frati, L., Antigenic expression changes occurring in adriamycin resistant MCF-7 mammary carcinoma cells. Anticancer Research, 1991, 11, 1225.
22. Dickstein, B., Valverius, E. M., Wosikowski, K., Saceda, M., Pearson, J. W., Martin, M. B. and Bates, S. E., Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. Journal of Cell Physiology, 1993, 157, 110.
23. Cianfriglia, M., Yassen, A., Tombesi, M., Samoggia, P., Barca, S. and Caserta, M., Expression of lymphocyte homing receptor gene is lost in multi-drug-resistant variants of human T-lymphoblastoid CCRF-CEM cells. International Journal of Cancer, 1991, 49, 394.
24. Cole, S. P., Pinkoski, M. J., Bhardwaj, G. and Deeley, R. G., Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. British Journal of Cancer, 1992, 65, 498.
25. Dixon, J., Kaklamanis, J., Turley, H., Hickson, I. D., Leek, R. D., Harris, A. L. and Gatter, K. C., Expression of aminopeptidase N (CD13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. Journal of Clinical Pathology, 1994, 47, 43.
26. Sedlak, J., McGown, A., Hrubisko, M., Hunakova, L. and Chorvath, B., Drug-resistance-associated alteration of cell surface antigens expression in a human anthracycline-resistant ovarian carcinoma cell line. Neoplasma, 1994, 41, 262.
27. Reddy, P. G., Graham, G. M., Datta, S., Guarini, L., Moulton, T. A., Jiang, H. P., Gottesman, M. M., Ferrone, S. and Fisher, P. B., Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. Journal of the National Cancer Institute, 1991, 83, 1307.
28. Fisk, B., Ioannides, C. G., Aggarwal, S., Wharton, J. T., O'Brian, C. A., Restifo, N. and Glisson, B. S., Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. Lymphokine and Cytokine Research, 1994, 13, 125.
29. Willingham, M. C., Cornwell, M. M., Cardarelli, C. O., Gottesman, M. M. and Pastan, I., Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Research, 1986, 46, 5941.
30. Zaman, G. J., Flens, M. J., van Leusden, M. R., de Haas, M., Mulder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F. and Broxterman, H. J., The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proceedings of the National Academy of Sciences U.S.A., 1994, 91, 8822.
31. Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. D., VanHeijningen, T. H. M., VanKalken, C. K., Slovak, M. L., DeVries, E. G. E., VanderValk, P., Meijer, C. J. L. M. and Pinedo, H. M., Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research, 1993, 53, 1479.
32. Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R. and Scheper, R. J., Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. International Journal of Cancer, 1996, 65, 230.
33. Ma, L., Krishnamachary, N. and Center, M. S., Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry, 1995, 132, 3338.
34. Gekeler, V., Boer, R., Ise, W., Snaders, K. H., Schachtele, C. and Beck, J., The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochemistry and Biophysics Research Communications, 1995, 206, 119.
35. Davies, R., Budworth, J., Riley, J., Snouden, R., Gescher, A. and Grant, T. W., Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. British Journal of Cancer, 1996, 73, 307.
36. Versantvoort, C. H., Schuurhuis, G. J., Pinedo, H. M., Eekman, C. A., Kuiper, C. M., Lankelma, J. and Broxterman, H. J., Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumor cells. British Journal of Cancer, 1993, 68, 939.
37. Geissler, J. F., Traxler, P., Regenass, U., Murray, B. J., Roesel, J. L., Meyer, T., McGlynn, E., Storni, A. and Lydon, N. B., Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. Journal of Biology and Chemistry, 1990, 265, 22255.
38. Takeda, Y., Nishio, K., Niitani, H. and Saijo, N., Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line. International Journal of Cancer, 1994, 57, 229.
39. Verovsky, V. N., Van den Berghe, D. L., Delvaeye, M. M., Scheper, R. J., De Neve, W. J. and Storme, G. A., Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. British Journal of Cancer, 1996, 73, 596.